24/7 Market News Snapshot 24 June, 2025 – InspireMD, Inc. (NASDAQ:NSPR)
DENVER, Colo., 24 June, 2025 (www.247marketnews.com) – (NASDAQ:NSPR) are discussed in this article.
InspireMD, Inc. has experienced a remarkable trading surge, with shares climbing an impressive 45.24% to $3.66 from a previous close of $2.52, reflecting heightened interest among investors and signaling potential market repositioning. The opening price for the trading session was $2.58, and the current trading volume is recorded at 1.48 million shares. Analysts and market participants are watching this momentum closely, as it may indicate further developments and opportunities in the stock.
Adding to the company’s buoyancy, InspireMD recently achieved a significant milestone with the U.S. Food and Drug Administration’s (FDA) approval of its CGuard Prime Carotid Stent System, designed for the treatment of carotid artery stenosis. This groundbreaking device received premarket application (PMA) approval following successful outcomes from the C-GUARDIANS pivotal trial, which demonstrated exceptional safety and efficacy. The trial, involving 316 patients across 24 sites in North America and Europe, revealed strikingly low rates of major adverse events—0.95% at 30 days and 1.93% at one year—making it a benchmark in carotid intervention studies.
Dr. D. Chris Metzger, who led the pivotal trial, emphasized the significant neuroprotective benefits of the CGuard Prime, framing it as a transformative solution for high-risk patients who might otherwise require carotid endarterectomy. Marvin Slosman, CEO of InspireMD, expressed enthusiasm over the milestone, highlighting the unique MicroNet mesh technology’s potential to redefine stroke prevention.
With over 65,000 global implants and substantial evidence from clinical studies involving more than 2,000 patients, InspireMD is poised for an aggressive U.S. market launch of CGuard Prime. This approval not only positions the company at the forefront of medical innovation but may also unlock a financial milestone up to $17.9 million, further supporting its ongoing commercial and developmental efforts in advancing patient care.